Eledon Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Eledon Pharmaceuticals, Inc. | ||
| Date: March 19, 2026 | By: | /s/ David-Alexandre C. Gros, M.D. |
|---|---|---|
| David-Alexandre C. Gros, M.D. | ||
| Chief Executive Officerand Director (PrincipalExecutive Officer and Duly Authorized Officer) | ||
| Date: March 19, 2026 | By: | /s/ Paul Little |
| Paul Little | ||
| Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ David-Alexandre C. Gros, M.D. | Chief Executive Officer and Director | March 19, 2026 |
| David-Alexandre C. Gros, M.D. | (Principal Executive Officer) | |
| /s/ Paul Little | Chief Financial Officer | March 19, 2026 |
| Paul Little | (Principal Financial and Accounting Officer) | |
| /s/ Keith A. Katkin | Chairman of the Board of Directors | March 19, 2026 |
| Keith A. Katkin | ||
| /s/ Jan Hillson, M.D. | Director | March 19, 2026 |
| Jan Hillson, M.D. | ||
| /s/ James Robinson | Director | March 19, 2026 |
| James Robinson | ||
| /s/ Allan Kirk, M.D. | Director | March 19, 2026 |
| Allan Kirk, M.D. | ||
| /s/ John S. McBride | Director | March 19, 2026 |
| John S. McBride | ||
| /s/ June Lee, M.D. | Director | March 19, 2026 |
| June Lee, M.D. | ||
| /s/ Steven Perrin | President, Director | March 19, 2026 |
| Steven Perrin | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.